Lantern Pharma Files 8-K
Ticker: LTRN · Form: 8-K · Filed: Jul 3, 2025 · CIK: 1763950
| Field | Detail |
|---|---|
| Company | Lantern Pharma Inc. (LTRN) |
| Form Type | 8-K |
| Filed Date | Jul 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
Lantern Pharma filed an 8-K on 7/3/25 for a material agreement. Details pending.
AI Summary
Lantern Pharma Inc. filed an 8-K on July 3, 2025, reporting the entry into a material definitive agreement and filing financial statements and exhibits. The filing does not contain specific details about the agreement or financial figures within the provided text.
Why It Matters
This filing indicates a significant corporate event or financial disclosure by Lantern Pharma, requiring investor attention.
Risk Assessment
Risk Level: low — The filing is a standard disclosure and does not inherently present new risks without further details.
Key Players & Entities
- Lantern Pharma Inc. (company) — Registrant
- July 3, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement filed by Lantern Pharma?
The provided text of the 8-K filing does not specify the details of the material definitive agreement.
What financial statements and exhibits were filed with this 8-K?
The filing indicates that financial statements and exhibits were included, but their specific content is not detailed in the provided text.
When was Lantern Pharma Inc. incorporated, and in which state?
Lantern Pharma Inc. was incorporated in Delaware.
What is Lantern Pharma's principal executive office address?
Lantern Pharma's principal executive office is located at 1920 McKinney Avenue, 7th Floor, Dallas, Texas 75201.
What is the IRS Employer Identification Number for Lantern Pharma Inc.?
The IRS Employer Identification Number for Lantern Pharma Inc. is 46-3973463.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 3, 2025 regarding Lantern Pharma Inc. (LTRN).